Kinnate Biopharma Inc Quick Ratio (KNTE) starting from the fourth quarter 2023 to fourth quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Kinnate Biopharma Inc   (NASDAQ: KNTE)

Kinnate Biopharma Inc 's Quick Ratio

KNTE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Kinnate Biopharma Inc 's Cash & cash equivalent, this led to improvement in Kinnate Biopharma Inc 's Quick Ratio to 13.87, Quick Ratio remained below Kinnate Biopharma Inc average.

Within Major Pharmaceutical Preparations industry 62 other companies have achieved higher Quick Ratio than Kinnate Biopharma Inc in fourth quarter 2023. While Quick Ratio total ranking has improved so far during the Q4 2023 to 280, from total ranking in the third quarter 2023 at 285.

Explain Quick Ratio?
How much Cash & cash equivalents KNTE´s has?
What are KNTE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KNTE Quick Ratio (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4
Y / Y Current Liabilities Change -35.32 % 2.81 % 37.59 % 32.95 % 38.59 %
Y / Y Cash & cash equivalent Change -32.2 % -34.91 % -29.61 % -25.63 % -10.22 %
Quick Ratio MRQ 13.87 10.62 11.71 11.07 13.23
KNTE's Total Ranking # 280 # 285 # 204 # 318 # 163
Seq. Current Liabilities Change -29.61 % 0.01 % -13.12 % 5.76 % 11.89 %
Seq. Cash & cash equivalent Change -8.08 % -9.27 % -8.1 % -11.54 % -11.75 %



Quick Ratio fourth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 63
Healthcare Sector # 110
Overall Market # 280


Quick Ratio Statistics
High Average Low
54.33 21.71 10.62
(Dec 31 2020)   (Sep 30 2023)




Financial Statements
Kinnate Biopharma Inc 's Current Liabilities $ 11 Millions Visit KNTE's Balance sheet
Kinnate Biopharma Inc 's Cash & cash equivalent $ 154 Millions Visit KNTE's Balance sheet
Source of KNTE's Sales Visit KNTE's Sales by Geography


Cumulative Kinnate Biopharma Inc 's Quick Ratio

KNTE's Quick Ratio for the trailling 12 Months

KNTE Quick Ratio

 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth 5.51 % 26.53 % 38.97 % 39.1 % 48.52 %
Y / Y Cash & cash equivalent TTM Growth -30.48 % -25.18 % -16.58 % -8.48 % 0.35 %
Quick Ratio TTM 11.63 11.67 13.1 15.26 17.65
Total Ranking TTM # 3296 # 3285 # 183 # 3112 # 2167
Seq. Current Liabilities TTM Growth -9.07 % 0.65 % 6.94 % 7.81 % 9.04 %
Seq. Cash & cash equivalent TTM Growth -9.37 % -10.33 % -8.2 % -6.81 % -2.48 %

Quick ratio ranking by company, industry and sector >> Back to KNTE Financial Strength Comparisons >> Go to Compare KNTE Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in KNTE's Current Liabilities to $11.10 millions, cumulative Quick Ratio to 11.63 below the KNTE average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 463 other companies have achieved higher Quick Ratio than Kinnate Biopharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2023 from 3285 to 3296.

Explain Quick Ratio?
How much Cash & cash equivalents KNTE´s has?
What are KNTE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 464
Healthcare Sector # 918
Within the Market # 3296


trailing twelve months Quick Ratio Statistics
High Average Low
23.19 17.51 11.67
(Mar 31 2022)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Climb Bio Inc   37.70 $ 106.798  Millions$ 2.833  Millions
Rafael Holdings Inc  36.93 $ 79.212  Millions$ 2.145  Millions
Tao Synergies Inc   34.18 $ 30.100  Millions$ 0.881  Millions
Design Therapeutics Inc   29.29 $ 281.798  Millions$ 9.622  Millions
Bicara Therapeutics Inc   28.62 $ 230.440  Millions$ 8.053  Millions
Morphic Holding inc   28.43 $ 704.349  Millions$ 24.776  Millions
Roivant Sciences Ltd   27.24 $ 6,670.810  Millions$ 244.899  Millions
Lixte Biotechnology Holdings Inc   26.81 $ 4.203  Millions$ 0.157  Millions
Upstream Bio Inc   26.41 $ 109.810  Millions$ 4.158  Millions
Karuna Therapeutics Inc   26.10 $ 1,262.813  Millions$ 48.392  Millions
Crinetics Pharmaceuticals Inc   26.04 $ 1,144.421  Millions$ 43.942  Millions
Akero Therapeutics Inc   24.42 $ 550.010  Millions$ 22.522  Millions
Belite Bio Inc  24.27 $ 88.157  Millions$ 3.633  Millions
Xenon Pharmaceuticals Inc   23.40 $ 638.082  Millions$ 27.273  Millions
Immunome Inc   23.37 $ 142.151  Millions$ 6.082  Millions
Anixa Biosciences Inc   23.06 $ 46.773  Millions$ 2.028  Millions
Nuvalent Inc   22.62 $ 719.905  Millions$ 31.823  Millions
Janux Therapeutics Inc   22.31 $ 344.028  Millions$ 15.422  Millions
Xbiotech Inc   22.25 $ 200.023  Millions$ 8.990  Millions
Astria Therapeutics Inc   21.97 $ 246.530  Millions$ 11.221  Millions
Pliant Therapeutics Inc   21.81 $ 495.544  Millions$ 22.724  Millions
Annexon Inc   21.11 $ 259.716  Millions$ 12.305  Millions
Spyre Therapeutics Inc   20.83 $ 339.277  Millions$ 16.290  Millions
Cadrenal Therapeutics Inc  20.72 $ 16.690  Millions$ 0.806  Millions
Ideaya Biosciences Inc   20.71 $ 525.114  Millions$ 25.354  Millions
Shattuck Labs Inc   20.29 $ 175.284  Millions$ 8.639  Millions
Rezolute Inc   19.60 $ 101.896  Millions$ 5.200  Millions
Diamedica Therapeutics Inc   19.57 $ 52.895  Millions$ 2.703  Millions
89bio Inc   19.55 $ 578.870  Millions$ 29.611  Millions
Lantern Pharma Inc   19.25 $ 51.555  Millions$ 2.678  Millions

Date modified: 2026-08-31T01:01:25+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.